Hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: Analysis of 114 cases

Kanzo/Acta Hepatologica Japonica

Volumn 52, Issue 7, 2011, Pages 449-460

  Urayama, Naoki ^a   Yamasaki, Takahiro ^a   Harimal, Yohei ^a   Saeki, Issei ^a   Zaitsu, Junichi ^a   Hamabe, Satoe ^a   Harano, Megumi ^a   Takami, Taro ^b   Kaino, Seiji ^a   Uchida, Kouichi ^a   Terai, Shuji ^a   Sakaida, Isao ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Advanced hepatocellular carcinoma; Hepatic arterial infusion chemotherapy; Molecular targeted agent; References; Response; Survival

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; INTERFERON;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHILD PUGH SCORE; DRUG RESPONSE; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HUMAN; LIVER CELL CARCINOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PREDICTION; SCORING SYSTEM;

EID: 80051877795     PISSN: 04514203     EISSN: 18813593     Source Type: Journal    
DOI: 10.2957/kanzo.52.449     Document Type: Article

References (36)

1. Japanese Source, (2004-2005). 2009
2. Japanese Source, 2009
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236
4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
5. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34
6. Japanese Source, 2010
7. Japanese Source, http://www.nexavar.jp/
8. Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese with hepatocellular carcinoma. Cancer Sci 2008; 99: 159-165
9. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649
10. Japanese Source, 2009
11. Ando E, Yamashita F, Tanaka M, et al. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997; 79: 1890-1896
12. Yamasaki T, Kurokawa F, Shirahashi H, et al. Novel arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. Hepatol Res 2002; 23: 7-17
13. Yamasaki T, Kurokawa F, Takami T, et al. Arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and isovorin for patients with advanced hepatocellular carcinoma, pilot study: Is a high dose of the biochemical modulator effective? Hepatol Res 2003; 27: 36-44
14. Yamasaki T, Kimura T, Kurokawa F, et al. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 2005; 40: 70-78
15. Takaki-Hamabe S, Yamasaki T, Saeki I, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: Is the addition of subcutaneous interferon-alpha-2b beneficial? Hepatol Res 2009; 39: 223-230
16. Okita K, Yamasaki T, Hamabe S, et al. Hepatic arterial infusion chemotherapy in combination with pegylated interaferon-a-2b for advanced hepatocellular carcinoma. Hepatogastroenterology in press
17. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 49-55
18. The Cancer of the Liver Italian Program (CLIPInvestigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751-755
19. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38: 207-215
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481
21. Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002; 94: 421-427
22. Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88: 1986-1991
23. Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-1997
24. Kim BK, Park JY, Choi HJ, et al. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2010; Jun 16
25. Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-595
26. Ota H, Nagano H, Sakon M, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 93: 557-564
27. Kurokawa Y, Matoba R, Nagano H, et al. Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma. Clin Cancer Res 2004; 10: 6029-6038
28. Hamada A, Yamakado K, Nakatsuka A, et al. Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma: prognostic factors. J Vasc Radiol 2004; 15: 835-841
29. Huo TI, Hsu CY, Huang YH, et al. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver Int 2010; 30: 198-207
30. Saito K, Inoue S, Saito T, et al. Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma. Gut 2002; 51: 100-104
31. Komura T, Mizukoshi E, Kita Y, et al. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol 2007; 102: 1939-1946
32. Yoshiji H, Noguchi R, Kitade M, et al. Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J Gastroenterol 2009; 44: 483-491
33. Harima Y, Yamasaki T, Hamabe S, et al. Effect of a late evening snack using branched-chain amino acid-enriched nutrients in patients undergoing hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Hepatol Res 2010; 40: 574-584
34. Japanese Source, 2008, 105, 808-816
35. Kudo M. Current status of molecularly targeted therapy for hepatocellular carcinoma. Int J Clin Oncol 2010; 15: 242-252
36. Japanese Source, 2010, 51, 684-685